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1087 The size of metastatic foci and lymph nodes yielding false-negative and false-
positive lymph node staging with positron emission tomography in patients
with lung cancer
Hiroaki Nomori, MD, PhD, Kenichi Watanabe, MD, Takashi Ohtsuka, MD, Tsuguo Naruke,
MD, PhD, Keiichi Suemasu, MD, PhD, and Kimiichi Uno, MD, PhD, Tokyo, Japan
The sizes of metastatic lymph nodes affecting false-negative and false-positive N staging by
PET were examined. PET could hardly detect metastatic foci smaller than 4 mm, not unusual
sizes for lymph node metastasis in lung cancer. None of the false-positive lymph nodes was
smaller than 9 mm.
1093 [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: Alternative
or diagnostic adjunct to 2-[18F]-fluoro-2-deoxy-D-glucose positron emission
tomography in the workup of suspicious central focal lesions?
G. Halter, MD, A. K. Buck, MD, H. Schirrmeister, MD, I. Wurziger, F. Liewald, MD,
G. Glatting, MD, B. Neumaier, MD, L. Sunder-Plassmann, MD, S. N. Reske, MD, and
M. Hetzel, MD, Ulm, Germany
The thymidine analogue [18F]FLT was suggested for imaging tumoral proliferation. In this
prospective study, we examined whether FLT-PET allows better differentiation of benign and
malignant pulmonary nodules compared with FDG-PET. Twenty-eight patients were examined.
The sensitivity of FLT-PET in detecting malignant tumors was 86%, and the specificity was
100%.
1100 Results of surgical intervention for p-stage IIIA (N2) non–small cell lung
cancer: Acceptable prognosis predicted by complete resection in patients
with single N2 disease with primary tumor in the upper lobe
Masayoshi Inoue, MD, PhD, Noriyoshi Sawabata, MD, PhD, Shin-ichi Takeda, MD, PhD,
Mitsunori Ohta, MD, PhD, Yuko Ohno, PhD, and Hajime Maeda, MD, PhD, Osaka, Japan
For heterogeneous patients with N2 non–small cell lung cancer (NSCLC), younger age,
squamous cell carcinoma, tumor in the upper lobe, c-N0, and single N2 status were identified
as better prognosis predictors. A good chance of survival is especially expected for patients
with single N2 NSCLC in the upper lobe removed by means of complete resection.
1107 Pulmonary metastases from uterine malignancies: Results of surgical
resection in 133 patients
Masaki Anraku, MD, Kohei Yokoi, MD, Ken Nakagawa, MD, Takehiko Fujisawa, MD, Jun
Nakajima, MD, Hirohiko Akiyama, MD, Yoshihiro Nishimura, MD, and Koichi Kobayashi, MD,
for the Metastatic Lung Tumor Study Group of Japan, Tochigi, Tokyo, Chiba, and Saitama,
Japan
The long-term results of the surgical treatment for patients with pulmonary metastases from
uterine malignancies were clarified. Pulmonary metastasectomy is an acceptable treatment and
provides favorable prognosis for patients with a disease-free interval of more than 12 months.
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1113 Intraoperative pleural lavage cytology is an independent prognostic
indicator for staging non–small cell lung cancer Œ
Eric Lim, MRCS, Ayyaz Ali, MRCS, Panagiotis Theodorou, MD, Andrew G. Nicholson,
FRCPath, George Ladas, FETCS, and Peter Goldstraw, FRCS, London, United Kingdom
To investigate the effect of pleural lavage cytology on survival after resection for non–small
cell lung cancer, we reviewed 292 patients over an 8-year period. Our results confirmed
positive pleural lavage cytology results as an independent predictor of prognosis that upstaged
patients to at least IIIB status.
1119 Risk of subsequent primary neoplasms developing in lung cancer patients
with prior malignancies
Malcolm V. Brock, MD, Anthony J. Alberg, PhD, Craig M. Hooker, MPH, Anne L. Kammer,
RHIT, CTR, Li Xu, BS, Carmen M. Roig, RN, and Stephen C. Yang, MD, Baltimore, Md
Of 8363 lung cancer patients, 11% had at least 1 prior malignancy. Subsequent cancers
occurred in 8%. The cumulative probability of developing a subsequent cancer did not differ
between those with and without a prior cancer diagnosis at 2 or 5 years.
1126 International experience with conversion from cyclosporine to tacrolimus for
acute and chronic lung allograft rejection
Kambiz Sarahrudi, MD, Marc Estenne, MD, Paul Corris, MD, Jost Niedermayer, MD,
Christiane Knoop, MD, Allan Glanville, MD, Cecilia Chaparro, MD, Geert Verleden, MD,
Margaret W. Gerbase, MD, Federico Venuta, MD, Heidi Bo¨ttcher, MD, John D. Aubert, MD,
Bronwyn Levvey, MD, Hermann Reichenspurner, MD, Alexandra Auterith, and Walter
Klepetko, MD, Vienna, Austria; Brussels and Leuven, Belgium; Newcastle, United Kingdom;
Hannover, Kiel, and Munich, Germany; Sydney, Australia; Toronto, Ontario, Canada; Geneva
and Lausanne, Switzerland; and Rome, Italy
Conversion from cyclosporine to tacrolimus in lung transplantation allows the control of
recurrent acute rejection and results in a decrease in the reduction of lung function in patients
with bronchiolitis obliterans syndrome.
Surgery for Acquired
Cardiovascular Disease
(ACD)
1133 Revascularization of multiple bypassable extended right coronary arteries
Mehmet Ras¸it Gu¨ney, MD, and Ergin Eren, MD, Istanbul, Turkey
Complete revascularization of extended right coronary arteries did not seem advantageous over
its conventional operation in patients with normal ventricular function; however, in patients
with poor ventricular function (ejection fraction 50%), it prevented perioperative ischemic
events in the right coronary artery territory and the consequent functional impairment that
appeared with conventional operation.
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